FDA Clears First OTC Continuous Glucose Monitor for Kids as Young as Two
The FDA cleared Dexcom's Stelo CGM for children 2+, offering real-time glucose tracking without a prescription for young users.
20 articles
The FDA cleared Dexcom's Stelo CGM for children 2+, offering real-time glucose tracking without a prescription for young users.
New wearable and non-invasive glucose monitors are transforming diabetes care โ here's what's available and how they work.
A software flaw in True Metrix glucose meters causes dangerous misreadings. FDA urges diabetics to switch devices immediately.
Adaptyx Biosciences unveils a wearable that monitors cortisol in real time, capturing hormonal rhythms conventional tests routinely miss.
A new health tech partnership merges diabetes management with cardiovascular monitoring to tackle cardiometabolic risk before complications arise.
Phase III trials show once-weekly CagriSema outperforms placebo on HbA1c and body weight in multiple type 2 diabetes populations.
Two adolescents with T1D and obesity saw major metabolic gains from low-dose semaglutide, cutting insulin needs and improving blood sugar control.
South Korea's hypertension guidelines now recommend cuffless ring monitors, marking a milestone for wearable BP tracking in clinical practice.
A new wearable claims to monitor estrogen, progesterone, LH and FSH in real time โ potentially transforming women's healthspan tracking.
A large 10-year study finds GLP-1 users develop cognitive impairment more often โ but mainly because they live longer to face it.
From new GLP-1 weight loss data to Omnipod recalls and semaglutide for nicotine addiction, here's what's moving in endocrinology.
A UC Berkeley spinout is developing a one-time gene therapy using transposons to sustain GLP-1 activity โ potentially replacing daily weight loss drugs.
A new jewelry-style wearable by Clair infers hormonal shifts in real time, challenging the once-a-year blood draw model of women's healthcare.
A 12-week study found Omada's wraparound GLP-1 program doubled fat loss and nearly tripled muscle preservation vs. controls.
A one-time endoscopic procedure helped patients retain 78% of GLP-1-induced weight loss one year after stopping the medication.
A smart ring joins hypertension guidelines for the first time globally, enabling silent overnight BP tracking that could catch deadly hidden spikes.
A large study confirms current CKD diagnostic thresholds hold up under gold-standard kidney testing, while revealing which biomarker combo predicts risk best.
Fractyl Health wins approval for a one-time pancreatic gene therapy that mimics natural GLP-1 signaling in type 2 diabetes patients.
A 12-week Omada Health study shows coaching and strength training dramatically improve fat loss and muscle retention alongside GLP-1 drugs.
The ACHIEVE-5 trial shows orforglipron added to basal insulin significantly lowered HbA1c and reduced body weight without raising hypoglycemia risk.